HomeCompareBAX vs RS

BAX vs RS: Dividend Comparison 2026

BAX yields 2.28% · RS yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RS wins by $5.91M in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
RS
RS
● Live price
1.61%
Share price
$300.49
Annual div
$4.85
5Y div CAGR
90%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$4,946,851.97
Full RS calculator →

Portfolio growth — BAX vs RS

📍 RS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXRS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + RS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
RS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
RS
Annual income on $10K today (after 15% tax)
$137.19/yr
After 10yr DRIP, annual income (after tax)
$4,204,824.17/yr
At 15% tax rate, RS beats the other by $4,204,815.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + RS for your $10,000?

BAX: 50%RS: 50%
100% RS50/50100% BAX
Portfolio after 10yr
$2.98M
Annual income
$2,473,431.11/yr
Blended yield
83.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BAX right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
RS
Analyst Ratings
9
Buy
16
Hold
2
Sell
Consensus: Hold
Price Target
$330.00
+9.8% upside vs current
Range: $320.00 — $340.00
Altman Z
6.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
RS buys
0
No recent congressional trades found for BAX or RS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXRS
Forward yield2.28%1.61%
Annual dividend / share$0.36$4.85
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%90%
Portfolio after 10y$20.6K$5.93M
Annual income after 10y$10.26$4,946,851.97
Total dividends collected$602.00$5.83M
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusHoldHold
Analyst price target$19.75$330.00

Year-by-year: BAX vs RS ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrRS PortfolioRS Income/yrGap
1← crossover$10,866$166.33$11,007$306.67$141.00RS
2$11,750$123.31$12,376$599.36$626.00RS
3$12,664$90.97$14,440$1,196.75$1.8KRS
4$13,617$66.89$17,930$2,479.30$4.3KRS
5$14,619$49.07$24,651$5,466.60$10.0KRS
6$15,679$35.94$39,723$13,346.12$24.0KRS
7$16,802$26.30$80,692$38,188.01$63.9KRS
8$17,998$19.23$224,087$137,747.25$206.1KRS
9$19,272$14.05$919,042$679,268.17$899.8KRS
10$20,631$10.26$5,930,227$4,946,851.97$5.91MRS

BAX vs RS: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

RSMaterials

Reliance Steel & Aluminum Co. operates as a diversified metal solutions provider and the metals service center company in the United States, Canada, and internationally. The company distributes a line of approximately 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium, and specialty steel products; and provides metals processing services to general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, and heavy industries. It also distributes non-ferrous metals products and tubular building products; and manufactures specialty extruded metals, fabricated parts, and welded components. As of December 31, 2021, the company operated a network of approximately 315 locations in 40 states in the United States and 13 in other countries. It sells its products directly to original equipment manufacturers, which primarily include small machine shops and fabricators. The company was founded in 1939 and is headquartered in Los Angeles, California.

Full RS Calculator →
📬

Get this BAX vs RS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.